Select Page

Kigali Rwanda, 12th December 2022 – Africa Centres for Disease Control and Prevention (Africa CDC) and Global Action for Fungal Infections (GAFFI) launch Diagnostics for fungal disease in Africa report at a side event during the 2nd International Conference on Public Health in Africa (CPHIA 2022).


Fungal disease of the lungs and brain is lethal if not diagnosed and treated early; and responsible for up to 50% of AIDS, 10-25% of TB, and 10-25% of leukaemia deaths. At the CPHIA 2022, which will take place from December 13-15, 2022, the lack of key diagnostics in many African countries is highlighted.


A two-year survey of 48 of the 55 countries in Africa – covering 99.65% of the 1.4 billion population – finds many diagnostics lacking or infrequently used. In partnership with Africa CDC, today, GAFFI issues a report of the status of the African continent with respect to 18 diagnostic procedures – most of these listed as Essential by the World Health Organization (WHO).


Dr Mohammed Abdulaziz, who leads the Division of Disease Control and Prevention at Africa CDC opened the meeting and declared:

 “The toll of fungal disease in vulnerable patients has gone unchecked for too long. We welcome this report and expect it to galvanise action to implement, in a stepwise fashion, improved diagnostics for serious fungal disease.


Cryptococcal meningitis:

Rapid testing was frequently done in 14 countries (358 million), but completely lacking in 22 countries (613 million).

Immediately fatal if not diagnosed and treated.


Pneumocystis pneumonia:

Molecular testing was only done in 8 countries, and 1,105 million are not covered.

Immediately fatal if not diagnosed and treated.


Fungus Aspergillus:

Long term infection can mimic TB of the lungs. The simple lateral flow assay for Aspergillus antibody to detect infection has been trialled in Uganda, DRC, Gambia, Sierra Leone, Benin, and Tanzania, but is only routinely available in Morocco – leaving 900 million without access.

Aspergillus lung infection has at least a 50% five-year mortality if untreated.


Cancer diagnosis:

Not possible without histopathology – regularly done in 19 countries (690 million), but completely lacking in 7 countries (46 million). To prevent death in leukaemia (and some intensive care patients) rapid fungal diagnosis with Aspergillus antigen is possible using a lateral flow assay (LFA). It is not available in 39 countries (1,032 million).


The launch meeting will highlight the ‘quick wins’ in initiating rapid diagnostics for fungal disease, combined with extensive training for laboratory staff and clinicians.




Professor Denning of GAFFI and the University of Manchester, who led the survey and report, stated: “The costs of testing are relatively low compared with high costs of premature death, inappropriate antibiotic use in mis-diagnosed cases, and long-term illness. If lower AIDS, TB, and cancer deaths are to materialise, fungal diagnostics are critical to that effort.”








Notes to Editors

The report in English and in French will be available here from December 12th, 2022. This includes individual country profiles for 48 countries.


About CPHIA 2022


The formal programme takes place 13-15 December 2022 in Kigali Convention Centre, Kigali, Rwanda. Official Side Events begin on 12 December.


The 2nd International Conference on Public Health in Africa (CPHIA 2022) is a three-day conference that will provide a unique platform for African researchers, policymakers, and stakeholders to come together and share perspectives and research findings in public health while ushering in a new era of strengthened scientific collaboration and innovation across the continent.

Conference theme: Preparedness for future Pandemic and Post-Pandemic Recovery: Africa at a Crossroad.


About the Africa Centres for Disease Control and Prevention (Africa CDC)


Africa CDC is the autonomous continental health agency of the African Union that strengthens the capacity and capability of Africa’s public health institutions as well as partnerships to detect and respond quickly and effectively to disease threats and outbreaks, based on data-driven interventions and programs. For more information, please visit:


About Global Action for Fungal Infections (GAFFI)


The high-level objective of GAFFI is to ensure that WHO Essential Diagnostics and Antifungal drugs are accessible to all and aligned to Universal Health Coverage. Vulnerable people from countries in the global south are disproportionately affected, and those afflicted with fungal disease live in misery due to morbidity, the inability to work, and the stigma. Limited diagnosis and poor measurement of disease morbidity means that the true scale of the problem is unknown. GAFFI has been a key global voice for fungal diseases in terms of public and global health since 2013.